Silverarc Capital Management’s Solid Biosciences SLDB Stock Holding History

Silverarc Capital Management’s Portfolio SLDB Stock Details SLDB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.68M	Buy	+668,450	New	+$5.07M	0.69%	45
2025 Q2	–	Sell	-452,239	Closed	-$1.67M	–	81
2025 Q1	$1.67M	Buy	+452,239	New	+$1.94M	0.34%	52
2024 Q4	–	Sell	-457,739	Closed	-$3.19M	–	78
2024 Q3	$3.19M	Sell	457,739 -15,256	-3%	-$124K	0.72%	39
2024 Q2	$2.68M	Sell	472,995 -852,070	-64%	-$7.63M	0.63%	41
2024 Q1	$17.6M	Buy	1,325,065 +730,210	+123%	+$6.83M	4.9%	2
2023 Q4	$3.65M	Buy	+594,855	New	+$1.9M	1.09%	35

Other funds holding SLDB

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Silverarc Capital Management's SLDB Position: Q2 2026 in Review

Silverarc Capital Management opened a new position in Solid Biosciences (SLDB) in Q2 2026: 668,450 shares worth $6.68M. The stake represents 0.69% of the portfolio and ranks #45 among its holdings. This is a return to the name: Silverarc Capital Management previously reported a position in SLDB as recently as Q1 2025.

Silverarc Capital Management first reported a position in SLDB in Q4 2023 and has held it in 6 quarters since. The position peaked at $17.6M in Q1 2024. 156 funds tracked by Wall St. Rank hold SLDB as of Q2 2026.

Silverarc Capital Management held 668,450 shares of Solid Biosciences worth $6.68M as of Q2 2026.
Solid Biosciences was a new Silverarc Capital Management position in Q2 2026.
Solid Biosciences made up 0.69% of Silverarc Capital Management's portfolio in Q2 2026, its #45 holding.
Silverarc Capital Management first reported a position in Solid Biosciences in Q4 2023 and has held it in 6 quarters since.
Silverarc Capital Management's Solid Biosciences position peaked at $17.6M in Q1 2024.
156 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2026.

Based on Silverarc Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.